Sight Sciences, Inc.

NasdaqGS SGHT

Sight Sciences, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 2.00

Sight Sciences, Inc. Price to Sales Ratio (P/S) is 2.00 on January 14, 2025, a -37.85% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Sight Sciences, Inc. 52-week high Price to Sales Ratio (P/S) is 5.23 on July 16, 2024, which is 162.01% above the current Price to Sales Ratio (P/S).
Sight Sciences, Inc. 52-week low Price to Sales Ratio (P/S) is 2.00 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
Sight Sciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 3.38.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: SGHT

Sight Sciences, Inc.

CEO	Mr. Paul Badawi
IPO Date	July 15, 2021
Location	United States
Headquarters	4040 Campbell Avenue
Employees	214
Sector	Consumer Discretionary
Industries Eyewear Medical Instruments Pharmaceuticals

Description

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Key trends

Past 5 years